FlowVax HPV is under development. FDA Approval is Required.
HPV (human papillomavirus) is the cause of virtually all cervical cancers and most oral-pharyngeal squamous cell cancers
Our T-cell immunotherapy for cervical and head & neck cancer targets HPV E6 and E7 Oncoproteins.
FlowVax HPV is delivered by intranodal injection.